Earnings Feed
Start Free
AbbVie Inc.·4

Feb 20, 6:36 PM ET

Thakkar Roopal 4

4 · AbbVie Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

AbbVie (ABBV) EVP Roopal Thakkar Receives Performance Stock Awards

What Happened

  • Roopal Thakkar, Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie, was reported as acquiring a total of 40,074 equity awards on Feb 18, 2026. The filing shows four awards of common stock/RSUs (6,015; 2,138; 3,346; 6,638 shares) and a derivative award of 21,937 (employee stock option). Each line is reported as an acquisition at $0.00 (awards/grants), so no cash was paid at grant. The performance-vesting restrictions for the RSU/performance share awards were certified as satisfied and released; those shares will be issued to Thakkar on February 28, 2026. The option award vests in annual increments beginning Feb 18, 2027 (7,313; 7,312; 7,312).

Key Details

  • Transaction date: February 18, 2026; Report filed: February 20, 2026 (timely).
  • Transaction type: A = Award/Grant; reported acquisition price $0.00; total shares awarded = 40,074.
  • Issuance/vesting: RSU/performance shares to be issued Feb 28, 2026 after Compensation Committee certification; option vests in annual increments on 2/18/2027, 2/18/2028 and 2/18/2029.
  • Shares owned after transaction: Not specified in this Form 4 filing.
  • Notable footnotes: Awards are performance-vesting and were released upon certification of performance goals (see F1–F4). The derivative entry (F5) is an employee stock option granted under AbbVie’s 2013 Incentive Stock Program and is exempt under Rule 16b‑3.
  • Filing timeliness: No late filing indicated.

Context

  • These were performance-based awards and an option grant, not open-market purchases or sales. The RSUs/performance shares were released after certification of goals and will be issued on Feb 28, 2026; the option grant vests over the next three years. Awards paid as compensation are common for executives and do not by themselves indicate a buy/sell signal.

Insider Transaction Report

Form 4
Period: 2026-02-18
AbbVie Inc.ABBV
Thakkar Roopal
EVP, R&D and CSO
Transactions
  • Award

    Common Stock, $0.01 par value

    [F1]
    2026-02-18+6,015→ 48,291 total
  • Award

    Common Stock, $0.01 par value

    [F2]
    2026-02-18+2,138→ 50,429 total
  • Award

    Common Stock, $0.01 par value

    [F3]
    2026-02-18+3,346→ 53,775 total
  • Award

    Common Stock, $0.01 par value

    [F4]
    2026-02-18+6,638→ 60,413 total
  • Award

    Option (Right to buy)

    [F5]
    2026-02-18+21,937→ 21,937 total
    Exercise: $230.04Exp: 2036-02-17→ Common Stock (21,937 underlying)
Footnotes (5)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029.
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Roopal Thakkar|2026-02-20

Documents

1 file
  • 4
    form4-02202026_110244.xmlPrimary